NCT04415073 is a Phase 2 clinical trial of SNDX-6352 in Coronavirus, sponsored by Syndax Pharmaceuticals.

Who is sponsoring NCT04415073?

NCT04415073 is sponsored by Syndax Pharmaceuticals.

What drugs are being tested in NCT04415073?

Interventions in NCT04415073: SNDX-6352, Placebo.

What condition does NCT04415073 study?

NCT04415073 studies Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome.

Is NCT04415073 still recruiting?

NCT04415073 is currently terminated. Last updated 22 July 2022.

Are results published for NCT04415073?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-07-22 · How we verify

NCT04415073

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Terminated Phase 2 Results posted Last updated 22 July 2022

What this trial tests

Phase 2 trial testing SNDX-6352 in Coronavirus in 1 participant. Terminated before completion.

Timeline

30 May 2020

Primary endpoint
13 July 2020

13 July 2020

Quick facts

Lead sponsor	Syndax Pharmaceuticals
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1
Start date	30 May 2020
Primary completion	13 July 2020
Estimated completion	13 July 2020
Sites	2 locations across United States

Drugs / interventions tested

SNDX-6352 — full drug profile →
Placebo

Conditions studied

Coronavirus — all drugs for Coronavirus →
COVID — all drugs for COVID →
ARDS — all drugs for ARDS →
Cytokine Storm — all drugs for Cytokine Storm →

Sponsor

Syndax Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Coronavirus or COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and symptoms secondary to COVID-19.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, et al · · 2021 · cited 126× · PMID 34473343 · DOI 10.1002/14651858.cd013825.pub2
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.
Patel S, Saxena B, Mehta P. · · 2021 · cited 39× · PMID 33553708 · DOI 10.1016/j.heliyon.2021.e06158
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Zhang J, Zhang H, Sun L. · · 2022 · cited 21× · PMID 35220888 · DOI 10.1080/19420862.2022.2031483
COVID-19 associated complications and potential therapeutic targets.
Monpara JD, Sodha SJ, Gupta PK. · · 2020 · cited 21× · PMID 32926918 · DOI 10.1016/j.ejphar.2020.173548
Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives.
Mayor A, Chesnay A, Desoubeaux G, Ternant D, et al · · 2021 · cited 9× · PMID 33668613 · DOI 10.3390/vaccines9020151
Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations.
Ji P, Chen J, Golding A, Nikolov NP, et al · · 2020 · cited 6× · PMID 32779201 · DOI 10.1002/jcph.1729

Verify or expand the search:

Other trials of SNDX-6352

Trials testing the same drug.

NCT04301778 — Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma · Phase 2 · completed

Other recruiting trials for Coronavirus

Currently open trials in the same condition.

NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting

Other Syndax Pharmaceuticals trials

Trials by the same sponsor.

NCT05731947 — Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors · Phase 1, PHASE2 · completed
NCT05406817 — Study of Radiolabeled Revumenib in Adults With Acute Leukemia · Phase 1 · completed
NCT05326516 — A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia · Phase 1 · completed
NCT04065399 — A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation · Phase 1, PHASE2 · recruiting
NCT03604692 — A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04415073 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Syndax Pharmaceuticals
Last refreshed: 22 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04415073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing